Faster-acting insulin aspart vs insulin aspart as part of basal–bolus therapy improves postprandial glycaemic control in uncontrolled Type 2 diabetes in the double-blinded onset 2 trial
Saravanan, P. Bowering, K. Case, C. Harvey, J. Reeves, M. Sampson, M. Strzinek, R. Bretler, D. M. Bang, R. B. Bode, B. W.
Saravanan, P.
Bowering, K.
Case, C.
Harvey, J.
Reeves, M.
Sampson, M.
Strzinek, R.
Bretler, D. M.
Bang, R. B.
Bode, B. W.
Citations
Altmetric:
Affiliation
University of Warwick; George Eliot Hospital, Nuneaton; University of Alberta, Canada; Jefferson City Medical Group, Missouri, USA; Bangor University, UK; Diabetes Clinical Trials, Chattanooga, Tennessee, USA; Norfolk and Norwich University Hospitals NHS Foundation Trust; Protenium Clinical Research, Hurst, Texas, USA; Novo Nordisk A/S, Søborg, Denmark; Atlanta Diabetes Associates, Georgia, USA
Other Contributors
Publication date
2017-03-08
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Poster abstract A46 (P110) in the section Science in clinical practice 1 from the Diabetes UK Professional Conference 2017, Manchester Central, Manchester, 8–10 March 2017.
Citation
Saravanan P, Bowering K, Case C, Harvey J, Reeves M, Sampson M, Strzinek R, Bretler DM, Bang RB, Bode BW. Faster-acting insulin aspart vs insulin aspart as part of basal–bolus therapy improves postprandial glycaemic control in uncontrolled Type 2 diabetes in the double-blinded onset 2 trial. Diabetic Medicine. 2017 Mar;34(S1):21. doi: 10.1111/dme.8_13303.
Type
Conference Output